Excyte Biopharma Ltd

This early-stage trial is testing a new drug called YK012 in 46 people with B-cell acute lymphoblastic leukemia (B-ALL). The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of fighting the cancer. Participants will receive YK012 throu…

This early-phase study is testing a new drug called YKST02 in 70 people with multiple myeloma that has relapsed or not responded to at least two prior treatments. YKST02 is a bispecific antibody designed to attach to both myeloma cells and immune cells, helping the immune system …

This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…

This study tests a new drug, YK012, in people with moderate to severe systemic lupus erythematosus (SLE). The drug is designed to target certain immune cells. The trial will check for safety, side effects, and early signs that the drug might help control lupus. About 189 adults a…

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check safety and how the body processes the drug, with a first look at whether it helps reduce protein in urine. P…